{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:37:24Z","timestamp":1791488244659,"version":"4.3.4"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.19092","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T15:33:03Z","timestamp":1628004783000},"page":"e2119092","source":"Crossref","is-referenced-by-count":19,"title":["Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire"],"prefix":"10.1001","volume":"4","author":[{"given":"Andrew","family":"Blake","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Smith","sequence":"additional","affiliation":[{"name":"Tuck School of Business at Dartmouth, Hanover, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"issue":"10","key":"zoi210567r1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/cid\/ciw111","article-title":"Rising mortality associated with hepatitis C virus in the United States, 2003-2013.","volume":"62","author":"Ly","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zoi210567r2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.v69.3","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016.","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"issue":"21","key":"zoi210567r5","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis.","volume":"380","author":"Thomas","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi210567r6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101554","article-title":"The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.","volume":"9","author":"Yehia","year":"2014","journal-title":"PLoS One"},{"key":"zoi210567r7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.drugalcdep.2019.02.008","article-title":"Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: low number treated.","volume":"198","author":"Morris","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"zoi210567r8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.drugalcdep.2018.11.026","article-title":"Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle.","volume":"195","author":"Tsui","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"zoi210567r9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/00333549161310S214","article-title":"Improving screening methods for hepatitis C among people who inject drugs: findings from the HepTLC Initiative, 2012-2014.","volume":"131","author":"Blackburn","year":"2016","journal-title":"Public Health Rep"},{"issue":"5","key":"zoi210567r10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cgh.2018.12.002","article-title":"Universal screening for hepatitis C: an important step in virus elimination.","volume":"17","author":"Chhatwal","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"zoi210567r11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugpo.2017.07.002","article-title":"Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review.","volume":"47","author":"Bajis","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi210567r12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/add.13948","article-title":"Scaling-up HCV prevention and treatment interventions in rural United States\u2014model projections for tackling an increasing epidemic.","volume":"113","author":"Fraser","year":"2018","journal-title":"Addiction"},{"issue":"5","key":"zoi210567r13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/cld.v12.5","article-title":"Rationing care: barriers to direct-acting antiviral treatment in Medicaid treatment criteria.","volume":"12","author":"Waters","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"3","key":"zoi210567r15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/PHH.0000000000000829","article-title":"Strategies for improving hepatitis C treatment access in the United States: state officials address high drug prices, stigma, and building treatment capacity.","volume":"25","author":"Kapadia","year":"2019","journal-title":"J Public Health Manag Pract"},{"key":"zoi210567r16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2019.05.028","article-title":"The opioid epidemic in rural northern New England: an approach to epidemiologic, policy, and legal surveillance.","volume":"128","author":"Stopka","year":"2019","journal-title":"Prev Med"},{"issue":"3","key":"zoi210567r18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/cid\/civ894","article-title":"The impact of enhanced screening and treatment on hepatitis C in the United States.","volume":"62","author":"Durham","year":"2016","journal-title":"Clin Infect Dis"},{"key":"zoi210567r19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.epidem.2019.02.003","article-title":"Hepatitis C transmission in young people who inject drugs: insights using a dynamic model informed by state public health surveillance.","volume":"27","author":"Gicquelais","year":"2019","journal-title":"Epidemics"},{"issue":"5","key":"zoi210567r20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3.","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Making"},{"issue":"6","key":"zoi210567r22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1001\/jama.2019.20844","article-title":"Reported heroin use, use disorder, and injection among adults in the United States, 2002-2018.","volume":"323","author":"Han","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"zoi210567r28","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/add.v113.9","article-title":"Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO\u2019s HCV elimination targets?","volume":"113","author":"Ward","year":"2018","journal-title":"Addiction"},{"issue":"1-3","key":"zoi210567r29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2009.01.006","article-title":"Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience.","volume":"102","author":"Roy","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"zoi210567r30","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.","volume":"9","author":"Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi210567r31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.drugalcdep.2014.03.029","article-title":"Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users.","volume":"140","author":"Nosyk","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"zoi210567r35","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1056\/NEJMp2002126","article-title":"People with hepatitis C who inject drugs\u2014underserved, not undeserving.","volume":"383","author":"Dore","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi210567r36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7326\/M14-0095","article-title":"The changing burden of hepatitis C virus infection in the United States: model-based predictions.","volume":"161","author":"Kabiri","year":"2014","journal-title":"Ann Intern Med"},{"issue":"10178","key":"zoi210567r37","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"zoi210567r38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/MOG.0000000000000524","article-title":"Fibrosis reversal after hepatitis C virus elimination.","volume":"35","author":"Rockey","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"issue":"3","key":"zoi210567r41","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/cid\/cix333","article-title":"Geographic disparities in access to syringe services programs among young persons with hepatitis C virus infection in the United States.","volume":"65","author":"Canary","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi210567r42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M18-3457","article-title":"Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study.","volume":"171","author":"Beetham","year":"2019","journal-title":"Ann Intern Med"},{"issue":"8","key":"zoi210567r44","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment.","volume":"105","author":"Jones","year":"2015","journal-title":"Am J Public Health"},{"issue":"6","key":"zoi210567r45","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2105\/AJPH.2017.303748","article-title":"Restrictions of hepatitis C treatment for substance-using Medicaid patients: cost versus ethics.","volume":"107","author":"Liao","year":"2017","journal-title":"Am J Public Health"},{"issue":"19","key":"zoi210567r46","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1001\/jama.2018.15782","article-title":"Alternative state-level financing for hepatitis C treatment: the \u201cNetflix model\u201d.","volume":"320","author":"Trusheim","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"zoi210567r48","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/COH.0b013e32834bd365","article-title":"HIV\/hepatitis C coinfection natural history and disease progression.","volume":"6","author":"Hernandez","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"zoi210567r21","author":"Romo","year":"2019"},{"key":"zoi210567r25","year":"2021"},{"key":"zoi210567r3","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016-2021\u2014towards ending viral hepatitis. 2016. Accessed March 13, 2020. https:\/\/apps.who.int\/iris\/handle\/10665\/246177"},{"key":"zoi210567r4","unstructured":"US Centers for Disease Control and Prevention. Viral hepatitis surveillance report 2018\u2014hepatitis C. Published November 18, 2020. Accessed January 4, 2021. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2018surveillance\/HepC.htm"},{"key":"zoi210567r14","unstructured":"The Policy Surveillance Program. Syringe service program laws. August 1, 2019. Accessed May 2, 2020. http:\/\/lawatlas.org\/datasets\/syringe-services-programs-laws"},{"key":"zoi210567r17","unstructured":"Meier? A, Moore? S, Saunders? E, . NDEWS hotspot report: understanding opioid overdoses in New Hampshire. 2018. Accessed March 13, 2020. https:\/\/umd.app.box.com\/v\/NDEWS-HotSpot-Report-June-2017"},{"key":"zoi210567r23","unstructured":"Department of Health and Human Services. Reportable communicable diseases in New Hampshire, 2015-2020 YTD. Accessed January 17, 2021. https:\/\/www.dhhs.nh.gov\/dphs\/cdcs\/publications.htm"},{"key":"zoi210567r24","unstructured":"New Hampshire Division of Public Health Services. Syringe services programs in New Hampshire: state fiscal year 2019 annual report. Accessed March 14, 2020. https:\/\/www.dhhs.nh.gov\/dphs\/bchs\/std\/documents\/sspreport-2018-2019.pdf"},{"key":"zoi210567r26","unstructured":"Substance Abuse & Mental Health Data Archive. Interactive NSDUH State Estimates. 2019. Accessed February 11, 2021. https:\/\/pdas.samhsa.gov\/saes\/state"},{"key":"zoi210567r27","unstructured":"New Hampshire Department of Health and Human Services. New Hampshire drug monitoring initiative. 2021. Accessed April 2, 2021. https:\/\/www.dhhs.nh.gov\/dcbcs\/bdas\/documents\/dmi-feb-2021.pdf"},{"key":"zoi210567r32","unstructured":"New Hampshire Department of Health and Human Services. New Hampshire drug monitoring initiative. 2019. Accessed September 7, 2020. https:\/\/www.dhhs.nh.gov\/dcbcs\/bdas\/data.htm"},{"key":"zoi210567r33","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health. Accessed July 24, 2020. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsq-reports\/NSDUHNationalFindingsReport2018\/NSDUHNationalFindingsReport2018.pdf"},{"key":"zoi210567r34","unstructured":"Substance Abuse & Mental Health Data Archive. Treatment episode data set: admissions (TEDS-A). 2018. Accessed March 13, 2020. https:\/\/www.datafiles.samhsa.gov\/study-series\/treatment-episode-data-set-admissions-teds-nid13518"},{"key":"zoi210567r39","unstructured":"Hepatitis C: state of Medicaid access. New Hampshire. 2017. Accessed August 12, 2020. https:\/\/stateofhepc.org\/report\/#NewHampshire"},{"key":"zoi210567r40","unstructured":"US Department of Health and Human Services. Hepatitis C Medicaid affinity group: supporting state-generated solutions to eliminating HCV. May 7, 2018. Accessed April 24, 2021. https:\/\/www.hhs.gov\/hepatitis\/hepatitis-c-medicaid-affinity-group\/index.html"},{"key":"zoi210567r43","unstructured":"US Centers for Disease Control and Prevention. Access to clean syringes. July 1, 2019. Accessed July 20, 2020. https:\/\/www.cdc.gov\/policy\/hst\/hi5\/cleansyringes\/index.html"},{"key":"zoi210567r47","unstructured":"US Centers for Disease Control and Prevention. Hepatitis C questions and answers for health professionals. January 13, 2020. Accessed March 19, 2020. https:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2782630\/blake_2021_oi_210567_1627324397.32731.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T15:33:41Z","timestamp":1628004821000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2782630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.19092","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]}}}